ClinicalTrials.gg
RecruitingNCT04861805VIVAUpdated Jun 29, 2025

Pivotal Study of the Vienna Transcatheter Self Expandable Aortic Valve SE System

An interventional study of Vienna Aortic Valve SE System in Symptomatic Aortic Stenosis, sponsored by P+F Products + Features GmbH. Recruiting at 31 sites in 8 countries. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2025-06-29.

Sponsored by P+F Products + Features GmbH · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year 1 month ago, but the record still lists the study as recruiting.
  • Started Jul 2023; still recruiting 3 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
267
Allocation
Not applicable
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 81 studies in Heart Diseases with a site in Spain — 25 open to participants now, 33 under way, 3 of them phase 3. Heart Diseases · Spain.

Planned enrollment
30th of 57
267 · median 300
Started
2023
with 5 others
No phase
24 of 81
7 open now
Primary completion
2025-10
later than 1 of 32 live
Registered
50th of 81
by date
Lead sponsor
3 of 81
P+F Products + Features GmbH

Among the 81 studies in Heart Diseases with a site in Spain, this one is the 30th largest by planned enrollment of the 57 interventional ones that give a count, is one of 6 that started in 2023, is one of 24 with no phase, reaches primary completion later than 1 of the 32 other live ones, and was the 50th registered.

Heart Diseases

2,135 studies on the registry are indexed under Heart Diseases; 250 are open to participants now.

Browse Heart Diseases studies →

Open to participants now

25 of the 81 studies in Heart Diseases with a site in Spain are open now. Recruiting first, the newest first:

19 more — sign in →

All 25 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 182 Heart Diseases studies recruiting now, 128 (70%) set no upper age limit and 22 (12%) stop at 75 or younger; 33 take children under 18; 41 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Heart Diseases with a site in Spain, or all of them as a file.
02

Study summary

This is a prospective, single arm, multicenter study in an cohort of up to 267 patients (up to 100 Roll-ins and 167 patients implanted per protocol) symptomatic patients with severe aortic stenosis who will be followed up for up to 5 years.

Read the detailed description

The purpose of this trial is to determine the safety and effectiveness of the Vienna Aortic Valve SE System, a new self-expanding transcatheter heart valve, in patients with symptomatic severe aortic stenosis (SSAS). This is a prospective, single arm, multicenter study in an expanding cohort of symptomatic patients with severe aortic stenosis following the FIH feasibility study. The clinical investigation comprises 11 visits (V1 to V11). After implantation of the IMD at visit 2, safety and effectiveness assessment of the device will be performed at 30 days (V4), 3 months (V5), 6 months (V6), 1 year (V7) and every year thereafter up to 5 years post-implantation (V8 to V11).

In summary, the clinical investigation for the individual patient will end after 5 years with a full clinical evaluation. The primary study endpoints for safety and effectiveness will be reached at 30-day follow-up timepoint.

The clinical trial is completed after all 267 patients, that are not prematurely withdrawn, have completed their 5-year follow-up visit involving all specified assessments.

03

Conditions studied

  • Symptomatic Aortic Stenosis

Browse trials for

Keywords

  • heart disease
  • aortic valve
  • SSAS
  • symptomatic severe aortic stenosis
  • heart valve
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or Female
  2. Age ≥ 65 years at time of consent
  3. Women of non-
  4. Severe degenerative calcific native aortic valve stenosis with the following criteria assessed either by resting or dobutamine stress TTE:

    1. Aortic valve area (AVA) \< 1.0 cm2 or AVA index ≤ 0.6 cm2/m2 and
    2. Jet velocity > 4.0 m/s or mean gradient > 40 mmHg
  5. Symptomatic aortic stenosis (AS), defined as a history of at least one of the following:

    1. Dyspnea that qualifies at class II or greater
    2. Angina pectoris
    3. Cardiac syncope
  6. Subject is considered at intermediate or high risk for surgical valve replacement based on at least one of the following:

    1. EuroSCORE II ≥ 4% along with assessment of frailty, major organ system dysfunction, and procedure-specific impediments, in accordance with scientific guidelines
    2. Agreement by the Heart Team that subject is at moderate to high operative risk of serious morbidity or mortality with surgical valve replacement.
  7. The local Heart Team deems the patient to be eligible for transfemoral TAVI.
  8. Perimeter-based aortic annulus diameter between ≥ 18 and ≤ 29 mm measured by computed tomography (CT) analyzed by a core lab.
  9. Adequate iliofemoral access with either:

    1. At least one side with minimum vessel diameter ≥ 6.0 mm and acceptable level of vessel calcification and tortuosity for safe placement of the introducer sheath, as analyzed by a core lab, OR
    2. At least one side with minimum vessel diameter ≥ 5.5 and no significant calcification or severe tortuosity for safe placement of the introducer sheath, as analyzed by a core lab.
  10. Patient (or legal representative) understands the study requirements and the treatment procedures and provides written .
  11. The patient and the treating physician agree that the patient will return for all required post-procedure follow-up visits.

Exclusion criteria

Exclusion Criteria:

Cardiovascular System:

  1. Patient has a congenital unicuspid or bicuspid aortic valve or non-calcified valves.
  2. Evidence of an acute myocardial infarction (MI) ≤ 30 days prior to screening or IMD implantation (defined as Q-wave MI or non-Q-wave MI with total CK elevation ≥ twice normal in the presence of CK-MB elevation and/or troponin elevation).
  3. Patient has had a cerebrovascular stroke or within the past 90 days implantation prior to screening or valve implantation.
  4. Patient has a hypertrophic obstructive cardiomyopathy.
  5. History of any therapeutic invasive cardiac procedure (including balloon aortic valvuloplasty) within 30 days prior to screening or IMD implantation (except for pacemaker implantation which is allowed).
  6. Untreated coronary artery disease requiring revascularization at the screening visit.
  7. Severe left ventricular dysfunction with (LVEF) \< 20% by echocardiography, contrast ventriculography, or radionuclide ventriculography.
  8. Patient with cardiogenic shock manifested by low cardiac output and hemodynamic instability and vasopressor dependence, or mechanical hemodynamic support
  9. Patients with clinically significant conduction abnormalities (clinically significant sinus bradycardia, sinus block or pauses, clinically significant atrioventricular (AV)-block >I) at screening and at time of IMD implantation.
  10. Patient has severe peripheral vascular disease:

    1. including aortic aneurysm defined as maximal luminal diameter > 5 cm or with documented presence of thrombus, marked tortuosity, narrowing of the abdominal aorta, severe unfolding of the thoracic aorta or thick [> 5 mm], protruding or ulcerated atheroma in the aortic arch) or
    2. symptomatic carotid or vertebral disease or successful treatment of carotid stenosis within 30 days prior to screening or IMD implantation.
  11. Patient with iliofemoral vessel characteristics that would preclude safe passage of the introducer (both sides), as analyzed by a core lab:

    1. severe calcification,
    2. severe tortuosity (> two 90-degree bends),
    3. diameter \< 6 mm, in patients with acceptable levels of calcification and acceptable levels of tortuosity
    4. diameter \< 5.5, in patients with no calcification and no significant tortuosity, OR
    5. subject has had an aorto-femoral bypass
  12. Patient with active bacterial endocarditis within 6 months prior to screening or IMD implantation.
  13. Patient has (echocardiographic/ CT and/or MRI) evidence of intra-cardiac mass, thrombus or vegetation.
  14. Patient has a pre-existing prosthetic heart valve in any position (Note: mitral ring is not an exclusion).
  15. Patient has severe mitral regurgitation, severe aortic regurgitation or severe tricuspid regurgitation, moderate or severe mitral stenosis.
  16. Patient has a need for emergency surgery for any reason at time of screening or IMD implantation.

    General:

  17. Any condition considered a for placement of a bioprosthetic valve (e.g. patient with contraindication to oral antiplatelet therapy)
  18. Patient with renal insufficiency ( \< 30 ml/min per the formula) and/ or renal replacement therapy and/ or has serum creatinine level > 3.0 mg/dL or 265 µmol/L replacement therapy at the time of screening
  19. Patient with significant pulmonary disease ( \< 30%) or currently on home oxygen
  20. Severe pulmonary hypertension (e.g., pulmonary artery systolic pressure ≥ 60 mmHg)
  21. Patients with evidence of an active systemic infection or sepsis.
  22. Patient has a known or contraindication to contrast media, bovine tissue, nitinol (titanium or nickel), contraindication to oral antiplatelet therapy (aspirin, ticlopidine or clopidogrel) or heparin.
  23. Patient has a \< 9 g/dL, count \< 50,000 cells/mm3 or > 700.000 cells/mm3, or white blood cell count \< 1.000 cells/mm3, history of bleeding diathesis or coagulopathy
  24. Patient has peptic ulcer disease or history of gastrointestinal bleeding within the 3 months prior to screening or IMD implantation.
  25. Patient refuses blood transfusions.
  26. Patient has a of less than 12 months due to non-cardiac, co-morbid conditions based on the assessment of the investigator at the time of enrolment (i.e. the time of ).
  27. Patient is pregnant or breast feeding.
  28. Severe dementia (resulting in either inability to provide informed consent for the study/procedure, prevents independent lifestyle outside of a chronic care facility, or will fundamentally complicate rehabilitation from the procedure or compliance with follow-up visits).
  29. Other medical, social, or psychological conditions that in the opinion of the Investigator precludes the patient from appropriate consent or adherence to the protocol required follow-up exams.
  30. Patient is currently participating in another drug or device study that has not reached its primary endpoint (excluding observational studies).
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
267 participants (estimated)

Study arms

  • Other
    Vienna Aortic Valve

    transcatheter aortic valve implantation (TAVI)

    Device: Vienna Aortic Valve SE System

Interventions

  • DeviceVienna Aortic Valve SE System

    Vienna Aortic Valve SE system for TAVI.

06

What researchers measure

Primary outcomes

  1. All Cause Mortality (30 days)

    All-cause mortality at 30 days from the index procedure.

    Time frame: up to 30 days

Secondary outcomes

  1. All-cause, cardiovascular and non-cardiovascular mortality

    All-cause, cardiovascular and non-cardiovascular mortality at 30 days, 3 months, 6 months, 1 year and every year thereafter up to 5 years post-implantation.

    Time frame: up to 5 years

  2. Periprocedural death

    Incidence of peri-procedural death (to capture intra-procedural events that result in immediate or consequent death ≤72 h post-procedure)

    Time frame: 72 hours

  3. Incidence of TAVI-related complications

    Incidence of TAVI-related complications: 1. Valve-related complication requiring repeat procedure 2. Vascular complications resulting in interventions 3. Ventricular septal perforation ≤7 days after IMD implantation 4. Acute kidney injury-Stage 2 or 3 ≤7 days post IMD implantation 5. Coronary artery obstruction requiring intervention 6. Atrio-ventricular block requiring pacemaker implantation 7. Mitral valve apparatus damage or dysfunction 8. Evidence of a new pericardial effusion/ tamponade related to the TAVI procedure 9. Prosthetic valve endocarditis 10. Prosthetic valve thrombosis 11. Prosthetic valve mispositioning 12. Prosthetic valve embolization 13. Valve-related dysfunction (mean aortic valve gradient ≥20 mmHg, EOA ≤0.9-1.1 cm2 and/or DVI peak velocity \>0.35 m/s, AND/OR moderate or severe prosthetic valve regurgitation)

    Time frame: periprocedural and during index hospitalization

  4. Cerebrovascular event

    Cerebrovascular event (at 30 days, 3 months, 6 months, 1 year and every year thereafter up to 5 years post-implantation): 1. Stroke, defined as an acute episode of focal or global neurological dysfunction caused by the brain, spinal cord, or retinal vascular injury as a result of haemorrhage or infarction 2. Transient ischemic attack (TIA), defined as a transient episode of focal neurological dysfunction caused by the brain, spinal cord, or retinal ischemia, without acute infarction. The difference between TIA and ischemic stroke is the presence of tissue damage on neuro-imaging studies or new sensory-motor deficit persisting \>24 h. By definition, a TIA does not produce a lasting disability.

    Time frame: Up to 5 years

  5. Life-threatening bleeding

    Life-threatening bleeding (at 30 days, 3 months, 6 months and 1 year post-implantation).

    Time frame: Up to 1 year

  6. Conduction disturbances requiring permanent pacemaker implantation

    Conduction disturbances requiring permanent pacemaker implantation (at 30 days, 3 months, 6 months, 1 year and every year thereafter up to 5 years post-implantation)

    Time frame: Up to 5 years

  7. Rehospitalization

    Re-hospitalization for valve-related complications or worsening congestive heart failure (at 30 days, 3 months, 6 months, 1 year and every year thereafter up to 5 years post-implantation)

    Time frame: Up to 5 years

  8. Device Success

    Device success defined as: a. correct positioning of a single prosthetic investigational heart valve in the proper anatomical location AND ability to provide appropriate hemodynamic AND absence of peri-procedural mortality within 72 hours after implantation

    Time frame: 72 hours

  9. Technical success

    Technical success defined as 1. successful vascular access, delivery and deployment of the IMD and successful retrieval of the delivery system; and 2. correct positioning of a single prosthetic investigational heart valve in the proper anatomical location 3. in patients alive at 30 days with implanted Vienna valve: 1. Total aortic regurgitation of none/trace/mild/mild-moderate 2. Patient prosthesis mismatch (PPM) insignificant\* 3. Mean gradient \< 20 mmHg

    Time frame: up to 30 days

  10. Clinical Efficacy

    Clinical efficacy (at 1 year and thereafter) 1. Freedom from all-cause mortality 2. Freedom from all stroke 3. Freedom from hospitalization for procedure- or valve-related causes 4. Freedom from KCCQ Overall Summary Score \<45 or decline from baseline of \>10 point (i.e. Unfavourable Outcome)

    Time frame: 1 year

  11. Valve-related clinical efficacy

    Valve-related clinical efficacy 1. Freedom from bioprosthetic Valve Failure (defined as: Valve-related mortality OR Aortic valve re-operation/re-intervention OR Stage 3 haemodynamic valve deterioration) 2. Freedom from stroke or peripheral embolism (presumably valve-related, after ruling out other non-valve aetiologies) 3. Freedom from VARC Type 2-4 bleeding secondary to or exacerbated by antiplatelet or anticoagulant agents, used specifically for valve-related concerns (e.g. clinically apparent leaflet thrombosis)

    Time frame: Up to 5 years

  12. New York Heart Association (NYHA) classification

    Change in heart failure symptoms from baseline as assessed by the New York Heart Association (NYHA) classification (at 30 days, 3 months, 6 months, 1 year and every year thereafter up to 5 years post-implantation)

    Time frame: Up to 5 years

  13. Change in quality of life as assessed by the Kansas City Cardiomyopathy

    Scale from 0 to 100 and summarized in 25-point ranges, where scores represent health status as follows: 0 to 24: very poor to poor; 25 to 49: poor to fair; 50 to 74: fair to good; and 75 to 100: good to excellent

    Time frame: 1 year

  14. Change in exercise capacity measured as the 6-minute walk distance (6-MWD)

    Change in exercise capacity from baseline measured as the 6-minute walk distance (6-MWD) (at 30 days, 3 months, 6 months and 1 year post-implantation)

    Time frame: 1 year

07

Study locations

18 of 31 sites recruiting
08

References and documents

Publications

  • Briedis K, Rumbinaite E, Aldujeli A, Briede K, Jurenas M, Jakuska P, Jankauskas A, Ceponiene I, Lenkutis T, Plisiene J, Benetis R, Zaliunas R. One-year initial efficacy and safety outcomes of the premounted dry-pericardium Vienna self-expandable transcatheter aortic valve system: A first-in-human VIVA feasibility study. Catheter Cardiovasc Interv. 2024 Jun;103(7):1111-1124. doi: 10.1002/ccd.31039. Epub 2024 Apr 9. PubMed 38591535 ↗
  • Briedis K, Aldujeli A, Zaliunas R, Benetis R. Early Safety and Performance of the Premounted Dry-Pericardium Vienna Self-Expandable Transcatheter Aortic Valve System: 30-Day Outcomes of the First-in-Human VIVA Feasibility Study. Am J Cardiol. 2023 Oct 1;204:302-311. doi: 10.1016/j.amjcard.2023.07.109. Epub 2023 Aug 9. PubMed 37567022 ↗
  • Briedis K, Mizariene V, Rumbinaite E, Jurenas M, Aldujeli A, Briede K, Jakuska P, Jankauskas A, Ceponiene I, Lenkutis T, Zaliunas R, Benetis R. Safety and performance of the Vienna self-expandable transcatheter aortic valve system: 6-month results of the VIVA first-in-human feasibility study. Front Cardiovasc Med. 2023 Jul 13;10:1199047. doi: 10.3389/fcvm.2023.1199047. eCollection 2023. PubMed 37522086 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2023 (actual). Primary completion is estimated for Oct 2025, 27 months after the start.

Of 73 industry-sponsored interventional studies with no phase under Heart Diseases, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 66. This study's planned 27 months is below that.

Counting every sponsor, half of 337 studies reached it within 25 months; a quarter within 11 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 20, 2021
First posted
Apr 27, 2021
StartActual
Jul 3, 2023
Primary completionEst.
Oct 2025
CompletionEst.
Oct 2030
Last update
Jun 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04861805
Lead sponsor
P+F Products + Features GmbH
Collaborators
Meditrial USA Inc.
Responsible party
Sponsor
First posted
Apr 27, 2021
Start date
Jul 3, 2023
Primary completion
Oct 2025 (estimated)
Completion
Oct 2030 (estimated)
Last update
Jun 29, 2025

Study contacts

Katharina Kiss, Dr
Contact
kkiss@productsandfeatures.com
+4369913289414
Monica Tocchi, MD, PhD
Contact
m.tocchi@meditrial.net
9176841700
Alexandre Abizaid, MD
principal investigator · Instituto do Coração (InCor) de São Paulo
Carla Agatiello, MD
principal investigator · Hospital Italiano de Buenos Aires
Alejandro Alvarez Iorio, MD
principal investigator · Hospital Privado Sur (FUMEBA)
Ignacio J Amat-Santos, MD
principal investigator · University Clinical Hospital of Valladolid
Rimantas Benetis, MD
principal investigator · Lithuanian University of Health Sciences
Pedro Braga, MD
principal investigator · Unidade Local de Saúde de Gaia e Espinho
Juan Horacio A Briales, MD
principal investigator · Hospital Virgen de la Victoria
João Brito, MD
principal investigator · Hospital de Santa Cruz
Duarte Cacela, MD
principal investigator · Hospital Santa Marta
Adriano M Caixeta, MD
principal investigator · Escola Paulista de Medicina da UNIFESP
Praveen Chandra, MD
principal investigator · Medanta - The Medicity Hospital
Christian Dauvergne, MD
principal investigator · Hospital del Tórax de Santiago
Pedro C Ferreira, MD
principal investigator · Hospital Santa Maria
John Jose E, MD
principal investigator · Christian Medical College Hospital
Rony Mathew Kadavil, MD
principal investigator · Lisie Hospital
Gabriel Maluenda, MD
principal investigator · Hospital Clínico San Borja Arriarán
Cesar R Medeiros, MD
principal investigator · Instituto Nacional de Cardiologia
Oscar Mendiz, MD
principal investigator · Fundación Favaloro
Sanjay Mehrotra, MD
principal investigator · Narayana Health Hospital
Marcio J Montenegro Da Costa, MD
principal investigator · Instituto Estadual de Cardiologia Aloysio de Castro
Cesar Morís de La Tassa, MD
principal investigator · Hospital Universitario Central de Asturias
Luis Nombela, MD
principal investigator · Hospital San Carlos, Madrid
Juan Oteo, MD
principal investigator · Hospital Puerta De Hierro
Lino MD Patrício, MD
principal investigator · Hospital do Espírito Santo de Évora
Osvaldo Perez, MD
principal investigator · Hospital Las Higueras - Talcahuano
Ravinder Singh Rao, MD
principal investigator · RHL - Rajasthan Hospital
Ángel S Recalde, MD
principal investigator · Hospital Universitario Ramón y Cajal
Ander Regueiro, MD
principal investigator · Hospital Clinic of Barcelona
Lluis A Serra, MD
principal investigator · Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Dimytri Siqueira, MD
principal investigator · Instituto Dante Pazzanese de Cardiologia
Hakan Ucar, MD
principal investigator · İ.A.Ü. VM Medical Park Florya Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion